Tie 2 Symposium

A World of Indications

For one small molecule, AKB-9778 has a huge potential.

Learn more...

World of Indications

New Approach for IBD

AKB-4924 strengthens the immune system and epithelial cells of the gut in preclinical models.

Learn more...

IBD Pill
Pipeline
(click on a compound for more information)
AKB-9778 AKB-4924
About

Aerpio Therapeutics is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases.

Learn more...
News

4/7/14 - Aerpio Therapeutics to Present at Needham Healthcare Conference

Read the press release.

2/13/14 - Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema

Read the press release.

11/6/13 - Aerpio Therapeutics Announces Successful Completion of Phase 1b/2a Trial in Diabetic Macular Edema and $9 Million Series A Extension

Read the press release.